These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 35312993)
1. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993 [TBL] [Abstract][Full Text] [Related]
2. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. Kadriu B; Greenwald M; Henter ID; Gilbert JR; Kraus C; Park LT; Zarate CA Int J Neuropsychopharmacol; 2021 Jan; 24(1):8-21. PubMed ID: 33252694 [TBL] [Abstract][Full Text] [Related]
3. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Johnston JN; Kadriu B; Allen J; Gilbert JR; Henter ID; Zarate CA Neuropharmacology; 2023 Mar; 226():109422. PubMed ID: 36646310 [TBL] [Abstract][Full Text] [Related]
4. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761 [TBL] [Abstract][Full Text] [Related]
5. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of ketamine action as an antidepressant. Zanos P; Gould TD Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791 [TBL] [Abstract][Full Text] [Related]
7. The role of eEF2 kinase in the rapid antidepressant actions of ketamine. Suzuki K; Monteggia LM Adv Pharmacol; 2020; 89():79-99. PubMed ID: 32616215 [TBL] [Abstract][Full Text] [Related]
8. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Aleksandrova LR; Phillips AG Trends Pharmacol Sci; 2021 Nov; 42(11):929-942. PubMed ID: 34565579 [TBL] [Abstract][Full Text] [Related]
9. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. Aleksandrova LR; Phillips AG; Wang YT J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212 [TBL] [Abstract][Full Text] [Related]
10. AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine. Yang C; Kobayashi S; Nakao K; Dong C; Han M; Qu Y; Ren Q; Zhang JC; Ma M; Toki H; Yamaguchi JI; Chaki S; Shirayama Y; Nakazawa K; Manabe T; Hashimoto K Biol Psychiatry; 2018 Oct; 84(8):591-600. PubMed ID: 29945718 [TBL] [Abstract][Full Text] [Related]
11. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways. Ren L Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110910. PubMed ID: 38061484 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of ketamine and its metabolites as antidepressants. Hess EM; Riggs LM; Michaelides M; Gould TD Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492 [TBL] [Abstract][Full Text] [Related]
13. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Monteggia LM; Gideons E; Kavalali ET Biol Psychiatry; 2013 Jun; 73(12):1199-203. PubMed ID: 23062356 [TBL] [Abstract][Full Text] [Related]
14. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review. du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962 [TBL] [Abstract][Full Text] [Related]
16. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Krystal JH; Kavalali ET; Monteggia LM Neuropsychopharmacology; 2024 Jan; 49(1):41-50. PubMed ID: 37488280 [TBL] [Abstract][Full Text] [Related]
17. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512 [TBL] [Abstract][Full Text] [Related]
18. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583 [TBL] [Abstract][Full Text] [Related]
19. Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Deyama S; Duman RS Pharmacol Biochem Behav; 2020 Jan; 188():172837. PubMed ID: 31830487 [TBL] [Abstract][Full Text] [Related]